<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Outlook Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/outlook-therapeutics-inc</link>
<description>Latest news and press releases for Outlook Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/outlook-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a77b78dffbe2df10bf8b.webp</url>
<title>Outlook Therapeutics Inc</title>
<link>https://6ix.com/company/outlook-therapeutics-inc</link>
</image>
<item>
<title>Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-closing-of-dollar50-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-closing-of-dollar50-million-registered-direct-offering</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per sh</description>
</item>
<item>
<title>Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-dollar50-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-4</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-dollar50-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-4</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical</description>
</item>
<item>
<title>Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-completes-federal-dispute-resolution-fdr-meeting-with-fda-for-ons-5010lytenavatm-bevacizumab-vikg-1</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-completes-federal-dispute-resolution-fdr-meeting-with-fda-for-ons-5010lytenavatm-bevacizumab-vikg-1</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Formal decision expected in May 2026 ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company</description>
</item>
<item>
<title>Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010lytenavatm-bevacizumab-vikg-accepted-by-fda</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010lytenavatm-bevacizumab-vikg-accepted-by-fda</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Announces Closing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-closing-of-dollar50-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-closing-of-dollar50-million-public-offering</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-pricing-of-dollar50-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-pricing-of-dollar50-million-public-offering</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-proposed-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-proposed-public-offering</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-new-dollar184-million-non-convertible-note-financing-and-amendment-to-existing-convertible-note</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-new-dollar184-million-non-convertible-note-financing-and-amendment-to-existing-convertible-note</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-update-following-type-a-meeting-with-fda-regarding-ons-5010lytenavatm-bevacizumab-vikg-67</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-update-following-type-a-meeting-with-fda-regarding-ons-5010lytenavatm-bevacizumab-vikg-67</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of</description>
</item>
<item>
<title>Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-expands-european-footprint-with-exclusive-commercial-distribution-agreement-with-mediconsult-ag-for-lytenavatm-bevacizumab-gamma-in-switzerland</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-expands-european-footprint-with-exclusive-commercial-distribution-agreement-with-mediconsult-ag-for-lytenavatm-bevacizumab-gamma-in-switzerland</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead</description>
</item>
<item>
<title>Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-reports-first-quarter-130500581</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-reports-first-quarter-130500581</guid>
<pubDate>Tue, 17 Feb 2026 13:05:00 GMT</pubDate>
<description>Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administration for ONS-5010 ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial</description>
</item>
<item>
<title>Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-submits-type-meeting-134500273</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-submits-type-meeting-134500273</guid>
<pubDate>Wed, 11 Feb 2026 13:45:00 GMT</pubDate>
<description>ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following receipt of a Complete Response Letter (CRL) dated December 30, 2025, regarding the Company’s Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-</description>
</item>
<item>
<title>Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-appoints-laura-cantrell-133500978</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-appoints-laura-cantrell-133500978</guid>
<pubDate>Tue, 06 Jan 2026 13:35:00 GMT</pubDate>
<description>ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “La</description>
</item>
<item>
<title>Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-regulatory-u-211500818</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-regulatory-u-211500818</guid>
<pubDate>Wed, 31 Dec 2025 21:15:00 GMT</pubDate>
<description>FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the ONS-5010/LYTENAVA™ (bevacizumab-vikg) biologics license application (BLA) resubmission, indicating</description>
</item>
<item>
<title>Outlook Therapeutics Announces New Employment Inducement Grants</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-employment-inducement-220000666</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-employment-inducement-220000666</guid>
<pubDate>Fri, 26 Dec 2025 22:00:00 GMT</pubDate>
<description>ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to</description>
</item>
<item>
<title>Outlook Therapeutics Reports Financial Results for Fiscal Year 2025</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-reports-financial-results-130500350</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-reports-financial-results-130500350</guid>
<pubDate>Fri, 19 Dec 2025 13:05:00 GMT</pubDate>
<description>ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and d</description>
</item>
<item>
<title>Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-present-piper-sandler-140500488</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-present-piper-sandler-140500488</guid>
<pubDate>Mon, 24 Nov 2025 14:05:00 GMT</pubDate>
<description>Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ETISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET. In</description>
</item>
<item>
<title>Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-acceptance-biologics-133000245</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-announces-acceptance-biologics-133000245</guid>
<pubDate>Thu, 13 Nov 2025 13:30:00 GMT</pubDate>
<description>Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic</description>
</item>
<item>
<title>Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-submits-biologics-license-133500972</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-submits-biologics-license-133500972</guid>
<pubDate>Mon, 03 Nov 2025 13:35:00 GMT</pubDate>
<description>ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025. ONS-5010 is an investigational ophthalmic formulation</description>
</item>
<item>
<title>Outlook Therapeutics Provides Update on Type A Meeting with FDA</title>
<link>https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-type-meeting-124500500</link>
<guid isPermaLink="true">https://6ix.com/company/outlook-therapeutics-inc/news/outlook-therapeutics-provides-type-meeting-124500500</guid>
<pubDate>Mon, 29 Sep 2025 12:45:00 GMT</pubDate>
<description>ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic fo</description>
</item>
</channel>
</rss>